Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and Evogene (NASDAQ:EVGN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.
Risk & Volatility
Mirum Pharmaceuticals has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Evogene has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.
Institutional and Insider Ownership
10.4% of Evogene shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of Evogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings for Mirum Pharmaceuticals and Evogene, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mirum Pharmaceuticals | 1 | 0 | 13 | 1 | 2.93 |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
Mirum Pharmaceuticals currently has a consensus target price of $155.56, indicating a potential upside of 58.94%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Evogene.
Profitability
This table compares Mirum Pharmaceuticals and Evogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mirum Pharmaceuticals | -134.75% | -97.25% | -12.59% |
| Evogene | -694.18% | -156.53% | -86.80% |
Earnings & Valuation
This table compares Mirum Pharmaceuticals and Evogene”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mirum Pharmaceuticals | $521.31 million | 12.26 | -$23.36 million | ($15.47) | -6.33 |
| Evogene | $3.85 million | 0.75 | -$8.48 million | ($0.91) | -0.36 |
Evogene has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.
Summary
Mirum Pharmaceuticals beats Evogene on 10 of the 15 factors compared between the two stocks.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
About Evogene
Evogene Ltd. is an Israel-based computational biology company founded in 2002. It uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and computational tools, to discover and develop products for agriculture, human health and other life-science applications. The company advances its work through subsidiaries and collaborations. Its businesses have included Casterra, which develops castor seed varieties, and Lavie Bio, which develops microbiome-based agricultural products.
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
